Navigation Links
Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/5/2009

RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:00 pm (PT) on Monday, January 12, 2009 at the J.P. Morgan Healthcare Conference in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS). Other therapeutic development programs are focused on HIV/AIDS, cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic areas including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
2. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
3. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
4. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
5. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
7. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
8. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
9. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
10. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
11. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/16/2017)... , ... July 16, 2017 , ... ... and analytical instruments announced the launch of its new line of Rocking and ... rocking and waving shaker models (both analog and digital) for laboratory applications in ...
(Date:7/14/2017)... ... July 14, 2017 , ... ... company . Sonic Manufacturing Technologies has installed a solar system on its roof ... three-year period,” the President of Sonic, Kenneth Raab stated. The company’s proud history ...
(Date:7/14/2017)... Denville, USA/ Martinsried, Germany (PRWEB) , ... July ... ... a newly developed standardized solution for sample preparation of proteins to clean peptides ... the Diagenode Bioruptor® sonication system. , The PreOmics iST Kit is based ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical SAS ... announced today the completion of a major transaction with Eurazeo PME. The reputable ... growth. The alliance fuels In’Tech Medical’s service offerings while leveraging the company’s manufacturing ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):